...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Potential

I certainly agree with you narmac. You are bang on as usual.

The science, what we are told of it, seems extremely promising.

Although there does not seem to be a business strategy it seems to me the possiblity of selling zen3694 to multiple BPs to enhance the the effectiveness and longevity of their drugs should be a very lucrative long term business.

We all know the problem. The business skill set does not exist at Zenith and it probably won't exist any time soon.

Thanks for your clear perspectives.

GLTA 

Toinv

Share
New Message
Please login to post a reply